NovoCure (NVCR) Expected to Announce Quarterly Earnings on Thursday

NovoCure (NASDAQ:NVCR) is expected to post its quarterly earnings results before the market opens on Thursday, February 27th. Analysts expect NovoCure to post earnings of ($0.34) per share and revenue of $161.30 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

NovoCure Stock Down 1.1 %

Shares of NovoCure stock opened at $21.00 on Wednesday. NovoCure has a 52-week low of $11.70 and a 52-week high of $34.13. The company has a 50 day moving average of $26.22 and a 200 day moving average of $21.42. The company has a quick ratio of 1.44, a current ratio of 1.49 and a debt-to-equity ratio of 0.27. The company has a market capitalization of $2.27 billion, a P/E ratio of -15.00 and a beta of 0.62.

Analyst Upgrades and Downgrades

NVCR has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $38.00 price objective on shares of NovoCure in a research report on Tuesday, January 14th. Evercore ISI upgraded shares of NovoCure from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $18.00 to $30.00 in a research report on Monday, December 2nd. Wedbush restated a “neutral” rating and set a $29.00 price objective on shares of NovoCure in a research report on Monday, January 13th. Finally, Piper Sandler boosted their price objective on shares of NovoCure from $28.00 to $42.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, NovoCure presently has a consensus rating of “Moderate Buy” and an average target price of $32.67.

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.